Characteristic Analysis of Early Gastric Cancer After Eradication: a Multicenter Retrospective Propensity Score-matched Study

Background: () is recognized as a type I carcinogen in gastric cancer (GC). However, GC still occurs after eradication, and its diagnosis is more complicated. This study aimed to summarize the characteristics of early GC (EGC) after eradication to help accurately identify EGC and avoid missed diagnosis and misdiagnosis.

Methods: A total of 81 patients of EGC after eradication (Hp-eradicated group), resected by endoscopic submucosal dissection (ESD), and 105 cases of infection-related EGC (control group) were assessed. After propensity-score matching, the clinical characteristics, endoscopic manifestations, and histopathological features of the 62 matched patients in each group were analyzed. We also conducted specific analyses in combination with endoscopic and histopathological images.

Results: There were more patients in the Hp-eradicated group who received proton pump inhibitor (PPI) for >1 year compared to the control group ( < 0.001). More patients at OLGA stages I-II before the diagnosis of EGC were in the control group ( = 0.045), especially at stage II. The mucosa in the Hp-eradicated group showed more moderate-to-severe atrophy ( = 0.047), map-like redness ( < 0.001) and mild activity ( < 0.001). The predominant histopathological types differed between the two groups ( < 0.001), and the majority of cases in the Hp-eradicated group were high-grade intraepithelial neoplasia (HGIN). Ki-67 expression was lower in the Hp-eradicated group ( = 0.025). But different eradication intervals of have little effect on the characteristics of EGC. Furthermore, PPI uses for >1 year ( = 0.005), mucosal map-like redness ( < 0.001), moderate mucosal atrophy ( = 0.017), and mild activity of gastric mucosa ( = 0.005) were independent characteristics of EGC after eradication.

Conclusion: Our multicenter study revealed that EGC after eradication was characterized by long-term PPI use, moderate mucosal atrophy, mucosal map-like redness, the mild activity of gastric mucosa, a higher proportion of HGIN cases, and lower levels of Ki-67.